Today’s Research Reports on Trending Tickers: CRISPR Therapeutics and Editas Medicine

NEW YORK, NY / ACCESSWIRE / May 31, 2018 / U.S. equities rebounded on Wednesday, lifted by strong performance from the energy sector and worries over Italy’s political crisis eased. The Dow Jones Industrial Average increased 1.26 percent to close at 24,667.78, while the S&P 500 Index climbed 1.27 percent to close at 2,724.01. The Nasdaq Composite Index was up 0.89 percent to close at 7,462.45.

“The fact that the market is shrugging off Italy’s political drama suggests that maybe it was a crowded trade that was being unwound and not something more serious,” said Michael Antonelli, equity sales trader at Robert W. Baird & Co.

“Anything coming from the left field can shatter markets nowadays, so we have to brace for a long summer grind,” Antonelli added.

RDI Initiates Coverage on:

CRISPR Therapeutics AG
https://rdinvesting.com/news/?ticker=CRSP

Editas Medicine, Inc.
https://rdinvesting.com/news/?ticker=EDIT

CRISPR Therapeutics’ stock jumped 6.79% Wednesday, to close the day at $73.59. The stock recorded a trading volume of 1,736,916 shares, which was above its three months average volume of 1,372,240 shares. In the last year, CRISPR Therapeutics’ shares have traded in a range of 13.54 – 73.90. The share price has gained 443.50% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $55.67 is above its 200-day moving average of $39.79. Shares of CRISPR Therapeutics have gained roughly 57.04 percent in the past month and are up 213.42 percent year-to-date.

Access RDI’s CRISPR Therapeutics AG Research Report at:
https://rdinvesting.com/news/?ticker=CRSP

On Wednesday, shares of Editas Medicine recorded a trading volume of 979,114 shares, which was below the three months average volume of 1,234,907 shares. The stock ended the day 6.4% higher at $37.93. The share price has fallen 15.75% from its 52 week high with a 52 week trading range of 13.20 – 45.02. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $34.49 is above its 200-day moving average of $32.95. Shares of Editas Medicine have gained roughly 20.8 percent in the past month and are up 23.43 percent year-to-date.

Access RDI’s Editas Medicine, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EDIT

Our Actionable Research on CRISPR Therapeutics AG (NASDAQ:CRSP) and Editas Medicine, Inc. (NASDAQ:EDIT) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 501346